Remotely Supervised Computerized Cognitive Stimulation to Reduce Post-chemotherapy Cognitive Difficulties in Patients Treated for Localized Breast Cancer

NCT06027632 · tracked via the Priya Life Science France tracker

Sponsor

Centre Francois Baclesse

Phase

Not applicable

Started

2024-02-09

Last updated

2025-09-19

Condition(s) studied

Breast CancerCognitive Dysfunction

Investigational drug(s) / intervention(s)

Cognitive exercises with supervisionCognitive exercises without supervision

Cognitive exercises with supervision: The experimental group will receive a 12-week intervention consisting of three 20-minute online cognitive stimulation sessions per week along with a weekly 30-minute centralized online remote supervision session with a neuropsychologist. Patient will also have access to the "PRESCO" program of the "HAPPYNeuron-Pro" software, which is designed to train up to 12 different cognitive domains, including attention, memory, executive functions and processing speed

Cognitive exercises without supervision: Patient will have access to the program named "PRESCO" of the "HAPPYNeuron-Pro" software, which is designed to train up to 12 different cognitive domains, including attention, memory, executive functions and processing speed

Study summary

Investigator propose the first French randomized comparative study to assess the efficacy of a remotely supervised online cognitive stimulation program, compared to an unsupervised online cognitive exercise intervention, in reducing cognitive complaints in localized breast cancer patients after adjuvant chemotherapy. Previous randomized studies have confirmed the effectiveness of online cognitive stimulation programs compared to standard care. The study seeks to determine the added value of remote supervision by a neuropsychologist. The control group will have access to the same online cognitive exercises as the experimental group but without supervision. Investigator has chosen not to include a wait-list group as it would be unethical to deny patients with cognitive complaints the opportunity to participate in an intervention expected to benefit them. The secondary objective is to evaluate the benefit of the supervised digitalized cognitive intervention on objective cognitive impairment.

The research hypothesis is that incorporating personalized remote support with supervision from a neuropsychologist into a digitalized cognitive stimulation program will reinforce the effectiveness of the intervention on cognitive complaints. This will be achieved by improving participation/adherence to the online cognitive stimulation program, as well as through the personalized supervision itself. Investigator believe that the supervision sessions, including educational components, will enable patients to identify their strengths, promote their cognitive awareness, and develop individualized strategies to apply their compensatory abilities in real-life situations. Since cognitive difficulties have multiple underlying causes, reducing these symptoms requires a multifaceted approach. The hypothesis is that combining cognitive training (which increases neuroplasticity and directly targets the cognitive domains affected by cancer and its treatments), with structured supervised educational sessions based on compensatory strategies, will yield better outcomes than online cognitive stimulation alone.

Eligibility

Sex

FEMALE

Min age

18 Months

Max age

—

Healthy volunteers

Inclusion Criteria: * Patient diagnosed with localized breast cancer * Age 18 or older, * Who have received adjuvant or neo-adjuvant chemotherapy and are currently undergoing adjuvant radiotherapy (ongoing hormone therapy, maintenance therapy other as target therapies or immunotherapy are permitted) until 6 months after end of radiotherapy. * Patients who report cognitive complaints that significantly impact their quality of life, as evaluated by the quality of life subscale of the FACT-Cog questionnaire. This subscale is composed by 4 questions: 1. I have been upset about these problems; 2. These problems have interfered with my ability to work; 3. These problems have interfered with my ability to do things I enjoy; 4. These problems have interfered with the quality of my life. Patients are eligible if their score on this subscale is at or below the 10th percentile, based on age guidelines and normative data (Lange et al., 2015), namely: * ≤ 8 for patients aged 30-49 years * ≤ 9 for patients aged 50-69 years * ≤ 10 for patients aged 70-89 years * Patients who have completed at least three years of primary school education, as determined by the Barbizet scale, * Patient with access to a functional laptop/computer with a keyboard, internet connection and an e-mail account - being able to use those tools alone, * Fluent in French, * Patients who have provided informed consent to participate in the study. Exclusion Criteria: * Personality disorder or any known progressive psychiatric pathology (e.g. schizophrenia), * Previous neurological history with ongoing cognitive symptoms (sequelae of head trauma, stroke, multiple sclerosis, epilepsy, neurodegenerative pathology, etc.), * Excessive alcohol intake or drug use, which could compromise participation to the intervention * Major visual and/or hearing deficit, * Patient who might not be able to complete neuropsychological testing, (including those with significant cognitive disorders that impede the completion of cognition tests, as determined by the cognitive screening test MoCA (MONTREAL COGNITIVE ASSESSMENT) and based on age and educational level according to GRECOGVASC (Reflection Group for Vascular COGnitive Assessment) normative data) * Already participating in a cognitive training program, * Refusal to participate, * Patient deprived of liberty or under guardianship, * Patient who might not be able to participate due to geographic, social or psychopathological reasons.

Primary outcome measure(s)

Average change in the score of the Perceived Cognitive Impairment (PCI) subscale score of the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) — After 12 weeks
Perceived Cognitive Impairment (PCI) score range 0-72 (The higher the score, the fewer cognitive complaints)

Trial sites (25)

Facility	City	Region	Status
Polyclinique Bordeaux Nord Aquitaine	Bordeaux	France	Not Yet Recruiting
Centre hospitalier de Bligny	Briis-sous-Forges	France	Recruiting
Centre François Baclesse	Caen	France	Recruiting
CH Métropole Savoie	Chambéry	France	Recruiting
Centre Jean Perrin	Clermont-Ferrand	France	Not Yet Recruiting
Centre George François Leclerc	Dijon	France	Not Yet Recruiting
Groupe Hospitalier Mutualiste de Grenoble	Grenoble	France	Recruiting
CHU de Limoges	Limoges	France	Recruiting
Centre Léon Bérard	Lyon	France	Recruiting
Institut Paoli Calmettes	Marseille	France	Recruiting
ICM Val d'Aurelle	Montpellier	France	Recruiting
Institut de Cancérologie de Lorraine	Nancy	France	Not Yet Recruiting
Hôpital privé du Confluent	Nantes	France	Recruiting
Centre Antoine Lacassagne	Nice	France	Recruiting
Clinique Haute Energie	Nice	France	Not Yet Recruiting
CHU de Nimes	Nîmes	France	Recruiting
Hôpital Saint-Louis	Paris	France	Not Yet Recruiting
La Pitié Salpétrière	Paris	France	Not Yet Recruiting
Centre hospitalier de Pau	Pau	France	Recruiting
Centre Arrmoricain d'Oncologie	Plérin	France	Not Yet Recruiting
Centre Eugène Marquis	Rennes	France	Recruiting
Centre Henri Becquerel	Rouen	France	Recruiting
Clinique Mathilde	Rouen	France	Recruiting
Clinique Medico-chirurgicale Charcot	Sainte-Foy-lès-Lyon	France	Not Yet Recruiting
Gustave Roussy	Villejuif	France	Recruiting

More Centre Francois Baclesse trials in France

Interest of a Weekly Consultation by a Medical Electro Radiology Manipulator (MERM) in Addition to the Follow-up by the Radiotherapist to Improve the Collection of Radio-induced Toxicities in Patients Undergoing Proton Therapy Active, not recruiting

TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma Recruiting

Interest of Bilateral Basic Tongue Mucosectomy Assisted by Robot or Laser in Combination with Tonsillectomy in the Assessment of Prevalent Cervical Lymphadenopathy Recruiting

Impact of Sleep Disturbance on Cognition and Quality of Life in Breast Cancer Recruiting

Evaluation of the Impact of Taking American Ginseng for 8 Weeks on Fatigue in Patients Treated for Localized Breast or Gynecological Cancer Recruiting

Other trials for the same condition

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors Recruiting

Screening and Care for Fear of Cancer Recurrence in Patients With Cancer at Institut Curie Recruiting

Development of Clinical and Biological Database Recruiting

Feasibility and Acceptability of Endoscopic Mastectomy in Patients With Breast Cancer Recruiting

Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06027632 on ClinicalTrials.gov ↗ ← All trials in France